Inovio Pharmaceuticals(US:INO) TMX Newsfile·2026-02-21 18:46Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on April 7, 2026 [1]. Group 1: Class Action Details - Investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 7, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing deficiencies [5]. - It is claimed that Inovio was unlikely to submit the INO-3107 Biologics License Application to the FDA by the second half of 2024 due to insufficient information [5]. - The lawsuit asserts that the overall regulatory and commercial prospects of INO-3107 were overstated, leading to material misstatements by the defendants [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has received recognition for its attorneys [4].